Investor Alert:

by James DiGeorgia, Analyst

Disruptive Artificial Intelligence Technology Could Trigger a Biotech Bonanza

Little-known Utah biotech on the forefront of a startling healthcare megatrend

  • Here are 7 Surprising Reasons this Artificial Intelligence (A.I.) – fueled megatrend could help early investors realize returns that soar as high as 989% 
  • Plus:  Which Billionaires Are Now Investing Millions of Dollars in this Space?  See Reason #7 to Find Out …

An under-the-radar biotech company – Utah-based Frélii, Inc. (OTCQB:FRLI– has made an astonishing breakthrough that could turn the healthcare industry upside down.

Watch this brief video for the full story now.

7 Surprising Reasons this Unstoppable Healthcare Revolution Could Change Your Life

They researched a revolutionary company that’s developed an Artificial Intelligence (AI) under the radar technology that could help people live longer…

By helping people live longer, healthier lives without outrageously expensive medical care or prescription drugs.

This company’s massive disruption of the medical industry could bring you the opportunity for profits of up to 989% — enough to turn $5,000 into $54,450. 

My name is James DiGeorgia and I’m the editor of World Opportunity Investor, a newsletter dedicated to building significant wealth by helping guide investors to get in early in breakthrough technologies, medicines and trends. Just see my latest recommendation…

Click here to get the full details in your Special Report – free of charge with your Risk-Free Trial Subscription to World Opportunity Investor. Or read on to learn more…

Here’s seven surprising reasons to consider investing in Frélii, Inc. (OTCQB:FRLInow…

Surprising Reason #1: This Disruptive Artificial Intelligence (A.I.) Breakthrough Could Lead to Longer, Healthier Lives

A stunning breakthrough in A.I. is set to rock the healthcare industry.

This breakthrough promises to cause massive disruption in both the areas of traditional medicine and nutritional supplements, as people will clamor to take advantage of this life-extending “miracle.”

And that rush of consumer demand could send the share price for little-known Frélii, Inc. (OTCQB:FRLI) soaring sharply higher.


Because this new technology can analyze an individual’s genetic profile and then precisely predict their future health risks decades in advance.

In other words, it can tell them if they’re likely to develop diabetes, cancers of the prostate, breast, lung, ovaries, and colon or many other conditions.

Right now, one young Utah-based company – Frélii, Inc. (OTCQB:FRLI) – offers consumers the world’s most complete genetic analysis.

It developed its trailblazing A.I. with an assist from coders at a giant global information technology company’s exclusive A.I. lab. The A.I. researchers at this company – an instantly recognizable firm worth over $775 billion – were so excited by the prospect of a breakthrough they made the unusual move of helping a potential competitor get its product to the market.

And that market could be vast because Frélii’s A.I.-powered service is aimed squarely at consumers … triggering a scenario for investors where Frélii, Inc. (OTCQB:FRLI) could deliver gains as high as 989% over the next 28 months – enough to turn every $5,000 invested into $54,450.

Frélii’s technology analyzes a person’s DNA so it can develop a full genome sequencing with 60,000,000+ individual data points. It then runs the data through its patented Artificial Intelligence, “Navi.”

Navi analyzes every data point against all existing published genomic studies.

This gives the consumer the most comprehensive genetic results on the planet and reveals their future health risks years or even decades in advance.

Better yet, Frélii’s A.I. will also recommend steps that could help the consumer avoid those health risks.

And it promises to bring massive disruption to the nutritional supplement industry by recommending specific supplements to help individuals overcome deficiencies that over time can lead to disease.

The A.I.’s clear implication for dramatically bettering human lives figures to drive explosive consumer demand.

And that demand will trigger a high-upside profit opportunity for investors who get in on this still-under-the-radar opportunity with Frélii, Inc. (OTCQB:FRLI).

Click here to claim a copy of a Special Investor’s Report I’ve prepared on this profit opportunity – yours free when you take a Risk-Free trial subscription to my World Opportunity Investor newsletter.

Surprising Reason #2: Frélii, Inc. (OTCQB:FRLI) is Well-Positioned for a Large, Ready-Made Market

Frélii, Inc. (OTCQB:FRLIhas the potential to generate significant revenues from a ready-made market of 19 million prospects.

Those 19 million prospects are the people who have already had their DNA tested by 23andMe and

While these DNA testing companies have proven popular, the data they analyze is fairly limited – only between 700,000 to 6 million bits of DNA data.

On the other hand, Frélii’s A.I. analyzes 60 million DNA data points.

With an analysis up to 10 times more thorough, it’s possible for Frélii to provide more precise, more accurate and more complete test results than anything consumers have seen to date.

Of course, the availability of such a more thorough analysis also means that the 19 million+ people who have already become customers of 23andMe or have demonstrated an interest in genomic analysis.

And these 19 million+ people own their DNA test results!

To go deeper with Frélii’s more thorough, A.I.-driven analysis, they merely have to upload the DNA data they already own to Frélii via a portal on Frélii’s website.

Then, for as little as $9 for 30 days access, or $108 year, Frélii’s precision genomic A.I. will use its 60 million DNA data points to develop precise health risk assessment and roadmaps to lower risk.

The potential upside in the consumer DNA testing market – thanks to high consumer demand – has drawn a great deal of attention in recent months

 In fact, major investors right now have their eyes on the direct-to-consumer DNA testing market … to the tune of hundreds of millions of dollars. For example…

  • Glaxo Smith Kline recently paid 23andMe $300 million for access to its database of human DNA. And, the $300 million only bought a limited, four-year collaboration aimed at discovering possible targets and treatments for human diseases.
  • Also in September 2018, 23andMe raised $250 million from Sequoia Capital. That brought its total venture capital investments to $491 million.

This type of investment from larger investors is significant because it shows the potential for a rapid rise in valuation for a company like Frélii, Inc. (OTCQB:FRLI).

My research shows that you could make better than 10 times your money.

Click here to claim a copy of a Special Investor’s Report I’ve prepared on this profit opportunity – yours free when you take a Risk-Free trial subscription to my World Opportunity Investor newsletter.

Surprising Reason #3: Frélii, Inc. (OTCQB:FRLI) Offers Investors High Upside Potential in Both the Near- and Long-Term

Investors looking to take advantage of this disruptive Artificial Intelligence technology opportunity should know that this is not simply a near-term opportunity.

 At the same time, this scenario is also not strictly a buy-and-hold opportunity where you invest thousands of dollars only to hope for a return several years down the road.

After careful analysis, I’ve issued a “Strong Buy” recommendation to my subscribers – and it’s one that comes with both near-term and long-term upside potential.

I’m projecting that shares of Frélii, Inc. (OTCQB:FRLI) could climb by nearly 100% over the next 12 months – a significant return on your money for a one-year investment.

But those investors willing to hold onto shares of Frélii, Inc. (OTCQB:FRLIcould see their money grow by 387% over a 20-month period … and potentially as much as 989% over the next 28 months.

Of course, there’s no guarantee when it comes to investing – but I’m very optimistic about the potential for significant growth in the value of Frélii, Inc. (OTCQB:FRLIin the months ahead.

Click here to claim a copy of a Special Investor’s Report I’ve prepared on this profit opportunity – yours free when you take a Risk-Free trial subscription to my World Opportunity Investor newsletter.

Surprising Reason #4: Soaring Demand for Personalized Healthcare Offers Huge Upside Potential for Investors

Frélii’s precision genomics unlocks the door to a radical new form of healthcare — personalized healthcare based on specific individual genomic data.

It means a woman with the BRAC/1 gene variant, that could cause deadly ovarian cancer, has advance warning of a cancer that’s hard to detect unless doctors know what they are looking for.

Using Frélii’s A.I., women can make a plan with their doctors that includes early detection of precancerous tissue before it turns into a cancer that spreads through their body. Because the sooner ovarian cancer is found and treated, the better the chances are for recovery.

Artificial Intelligence Is the Key to Superb Human Health

However, Frélii’s A.I. does more than just identify a person’s individual nutrition needs. It can also identify the most effective prescription drug treatments based on a precise genomic analysis.

All you have to do is look at your health insurance company’s formulary — the list of drugs it covers — to understand how important Frélii’s A.I. could become.

Fortunately, Frélii’s Artificial Intelligence has “learned” the compounds that make up most every drug. That’s how it can make a genetic match for the chemicals in the drugs that will yield the most effective individual treatment.

A World of Opportunity With Frélii, Inc. (OTCQB:FRLI)

This is just another reason why Frélii (OTCQB:FRLI) could be such a great special situation investment. It’s that brief moment when science fiction suddenly becomes reality and the stock of an under-the-radar company can potentially soar.

There’s likely no bigger game-changer today than all the ways A.I. is revolutionizing medicine.

That’s why every farsighted investor needs to focus on Frélii, Inc. (OTCQB:FRLI). Its A.I. breakthrough has the potential to launch Frélii’s share price by as much as 989% over the next 28 months.

Click here to claim a copy of a Special Investor’s Report I’ve prepared on this profit opportunity – yours FREE when you take a Risk-Free trial subscription to my World Opportunity Investor newsletter.

Surprising Reason #5: Frélii, Inc.’s (OTCQB:FRLI) Breakthrough Threatens Massive Disruption for the Alternative Health Industry

In addition to its progress in the area of traditional medicine, Frélii’s A.I. has also made another huge step forward in personalized individual health strategies – and it’s one that threatens to bring massive disruption to the booming alternative health industry.

Nutritional supplements have become exceptionally popular because of the role they play in dramatically helping people overcome deficiencies in certain nutrients within their body.

Because everyone’s body is different, each individual may have different requirements for vital nutrients … and supplements help fill those requirements that aren’t met naturally.

But instead of playing a guessing game – or correcting a deficiency well after-the-fact – Frélii’s breakthrough is able to provide an individualized evaluation of your nutrient needs.

For example, maybe you have too much Vitamin D in your body. Frélii’s A.I.-driven platform would detect this and let you know how you could adjust your diet or supplementation to account for the excess Vitamin D.

Or maybe you have too little Vitamin C in your body. Again, Frélii’s technology would help you adjust your nutrition plan so you know to take more Vitamin C.

Instead of a “one-size-fits-all” approach to alternative health – where people are taking too much or too little of a particular supplement … or not taking something they need to be taking – Frélii’s breakthrough will be able to tell you what you need to do to build up your immune system.

This will allow more people to remain healthy – and take care of nutritional deficiencies – in a far more effective manner than is available today.

Simply put, it’s a revolutionary breakthrough in the alternative medicine space – and it promises to change consumers’ approach to nutritional supplements forever.

Frélii, Inc. (OTCQB:FRLIrecognizes the outsized potential for this new approach and has already begun stocking a variety of nutritional supplements it can sell to its clients to optimize their nutrient balance.

This customization of nutritional needs will turn into a nutritional supplement megatrend that figures to generate attention from the mass media – and from investors all over the world.

That attention will likely have a demonstrative impact on the share price for Frélii, Inc. (OTCQB:FRLI). The good news is that you still have time to invest in this megatrend in the early stages – before the trend potentially moves the share price for Frélii, Inc. (OTCQB:FRLIsharply higher.

Click here to claim a copy of a Special Investor’s Report I’ve prepared on this profit opportunity – yours FREE when you take a Risk-Free trial subscription to my World Opportunity Investor newsletter.

Surprising Reason #6: More Investors are Eyeing the Red-Hot Genomic Research Industry for Profit Opportunities

The global genetic testing market is projected to surpass $22 billion in the next five years, according to a new research report by Global Market Insights.

And with its disruptive A.I.-powered breakthrough, Frélii, Inc. (OTCQB:FRLIis well-positioned to grab a large chunk of that business – and quickly.

The stunning growth is being fueled by a growing awareness of direct-to-consumer (DTC) testing and the idea that early detection will lead to timely treatments, which in turn will lead to longer lifespans.

That’s because DTC DNA tests can reveal the potential for health problems, such as cancer, which claimed the lives of 6,000,920 Americans in 2017 alone.

Moreover, as science advances, more people and doctors will seek testing in order to get early diagnosis of diseases.

And, with the exception of one public company — Frélii, Inc. (OTCQB:FRLI) which offers in-depth precision genomic health risk assessment — investments in the emerging industry are available only to hedge funds and venture capitalists because the field is populated by privately held companies.

These are the leading privately held DTC DNA testing companies:

  • HABIT — for $299, Habit offers personalized diet plans based on a blood test that users give themselves.
  • WELLNESS FX — offers four diagnostic plans that range in price from $198 to $925. Personal consultations are extra.
  • FITNESS GENES — for $249, it offers tailored fitness routines based on DNA. It also suggests nutrition plans and personal trainers.
  • 23andME — along with family tree DNA tests, the government has now cleared it to offer health risk assessment for 10 diseases.

That means in a DTC industry dominated by private companies, Frélii is a Main Street investor’s only access to the emerging direct-to-consumer DNA/genomic testing megatrend.

Ultimately, the recent advancements in genomic sequencing by companies using Artificial Intelligence, such as Frélii, Inc., offer the tremendous promise of investing success by forever altering the world of healthcare for the better.

Click here to claim a copy of a Special Investor’s Report I’ve prepared on this profit opportunity – yours FREE when you take a Risk-Free trial subscription to my World Opportunity Investor newsletter.

Surprising Reason #7: Billionaires Bankroll Biotech Pioneers in Drive to Live Longer, Healthier Lives

 A FORBES headline once asked… “Who Wants To Live Forever?…The Super-Rich, That’s Who (And Most Everyone Else).”

It turns out that not only do many of the super-rich want fantastically long lifespans and healthspans, but a good number of them are investing their own money to make it happen.

Seemingly invincible in every other way, some of the world’s super wealthy are in a race against time. They want to stay alive until revolutionary solutions for making huge gains in healthy life extension can be discovered.

While most people consider old age unavoidable, tech billionaires Peter Thiel, PayPal’s cofounder, and Amazon founder Jeff Bezos each seem to find the notion of dying unacceptable.

Jeff Bezos and Peter Thiel Invest in the Cutting Edge Field of Extending Healthspans

Bezos and Thiel were the leaders that helped put together a $200 million cash infusion into a startup called Unity Biotechnology (NASDAQ:UBX) prior to its IPO.

Founded in 2009, Unity saw the millions flow from a mix of venture funds, and tech investors, including Jeff Bezos’ Bezos Expeditions, Paul Allen’s Vulcan Capital, Peter Thiel’s Founders Fund, and Venrock, which is a Rockefeller family venture fund.

Unity went public in 2018 and is now estimated to be worth $700 million.

Of course, Frélii, Inc. (OTCQB:FRLIhas such a powerful – and game-changing – A.I.-powered breakthrough, it could also soon attract the attention of both billionaire investors as well as Main Street investors.

That’s because Frélii, Inc. (OTCQB:FRLI) right now offers the best way to play the trend toward using technology to help live longer, healthier lives.

And that type of attention could mean great times ahead for the company’s share price.

Bottom Line: I’m Recommending Frélii, Inc. (OTCQB:FRLI) as a “Strong Buy” to My Newsletter Subscribers 

After running the numbers — and examining the company closely — I believe Frélii, Inc. (OTCQB:FRLIis a one-of-a-kind company with a competitive advantage that gives it the potential to boost its share price nearly 11 times over the next 28 months. 

To help explain how this scenario could unfold, I’ve prepared a comprehensive Special Report on this opportunity called In the Age of Precision Genomics, Every Investor Needs To Own Frélii, Inc.

You’ll receive a FREE copy of this Special Report when you accept a risk-free trial subscription to my World Opportunity Investor newsletter. Plus, you’ll receive up to six FREE bonus gifts designed to help grow and protect your wealth.

While Frélii is a tad more aggressive for me than usual, it’s a good example of the deep research I cover in my monthly newsletter, World Opportunity Investor.

However, to reiterate my caution, please remember that risk and reward are joined at the hip.

As much as I think Frélii’s A.I. precision genomics could be a shoo-in to hand early investors an outsized return, I’m not encouraging you to mortgage the house and buy every share you can get your hands on.

With that said, I’m recommending Frélii, Inc. (OTCQB:FRLI) because it’s the rare young company that could actually disrupt a mature marketplace.

If that happens, the sky’s the limit. A 989% gain is enough to turn $5,000 into $54,450. And, I think that could happen in the next 28 months.

I’ll be following Frélii closely in the pages of my monthly World Opportunity Investor newsletter.

And I’m happy to extend to you a special offer to subscribe to World Opportunity Investor for one year (12 monthly issues) for just $72 — a 54% discount off the regular subscription price.

In addition to the newsletter, you’ll have free access to my daily podcast or video briefing on important market action and trends, as well as updated information about my recommended stocks.

For more information about World Opportunity Investor, simply click the button below. Or, to subscribe now and claim your FREE Special Report, Call Toll Free 1-800-718-8923 (Mon – Fri, 9am – 7pm EST)

What YOU Should Consider Now

  • Go online or call your discount broker to invest in Frélii Inc. (OTCQB:FRLI)​​
  • Click the button below to claim your RISK-FREE trial subscription to World Opportunity Investor today…Plus you’ll receive up to six bonuses valued at $374 absolutely FREE as well as breaking news and buy, hold and sell updates about this disruptive Artificial Intelligence breakthrough! 

Call Toll Free 1-800-718-8923 (Mon – Fri, 9am – 7pm EST)

More About James DiGeorgia, Analyst

30 Years of Uncanny Success is Marked by an Uncanny Knack: Be the First to Spot New Emerging Megatrends

James DiGeorgia, Analyst

For more than 30 years, analyst James DiGeorgia has helped investors make money – in any kind of market – by spotting winning investments well ahead of the crowd.

James started his first business while still in high school, and made his first million before he turned 21! After completing an economics degree in just 2 ½ years, he wrote several best-selling books about investing and served as editor of the most profitable investment advisory services in the world:

  • Gold and Energy Investor — a 20% average annual track record for 10 years in a row.
  • SuperStock Investor — a 72.57% total average for 7 years.
  • Options Index Trader — wins added up to 276.59% in just 33 months!
  • Gold and Energy Options Trader — a 486% average annual win 11 years in a row and counting!

His latest endeavor is World Opportunity Investor, a newsletter that shows individual investors how to cash in on disruptive technologies such as the Artificial Intelligence, personalized DNA testing, and the personalized healthcare megatrend that are highlighted on this page.

Today, this legendary moneymaker is forecasting that a little-known company called Frélii, Inc. (OTCQB:FRLIhas the potential to deliver a better than 10X gain.


All investments are subject to risk, which must be considered on an individual basis before making any investment decision. World Opportunity Investor is an investment newsletter being advertised herein. This paid advertisement includes a stock profile of Frélii Inc. (OTC: FRLI). This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to buy or sell, or as a solicitation to buy or sell, any securities.  In an effort to enhance public awareness of FRLI and its securities, TGB MEDIA LIMITED (Payor) provided advertising agencies with a total budget of approximately two million, one hundred eighty-three thousand, six hundred sixteen dollars to date to cover the costs associated with creating, printing and distribution of this advertisement for World Opportunity Investor. FRLI was chosen to be profiled in this advertisement after World Opportunity Investor conducted an investigation of the company. World Opportunity Investor was paid thirty thousand dollars as a research fee. In addition, World Opportunity Investor may receive subscription revenue in the future from new subscribers as a result of this advertisement. The advertising agencies will retain any excess sums after all expenses are paid. As of the date these materials are disseminated, neither the advertising agencies nor World Opportunity Investor nor any of their respective officers, principals or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) own or beneficially own any securities of FRLI.  Neither the advertising agencies nor World Opportunity Investor or any of their respective officers, principals or affiliates will purchase or receive any securities of FRLI for a period of ninety (90) days following the date this advertising campaign is concluded. The Payor has represented in writing to World Opportunity Investor and the advertising agencies that neither the Payor nor any of its officers, directors, principals or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) owns or beneficially owns any securities of FRLI or will purchase or receive any securities of FRLI for a period of ninety (90) days following the conclusion of this advertising campaign. If successful, this advertisement will increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of FRLI, increased trading volume, and possibly an increased share price of FRLI’s securities, which may be temporary. This advertisement, the advertising agencies and World Opportunity Investor do not purport to provide a complete analysis of this company’s financial position. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent publicly-available information about the company and its industry. Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in FRLI’s SEC filings. Investing in micro cap securities such as FRLI is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agencies and World Opportunity Investor cannot guarantee the accuracy or completeness of the information and are not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of FRLI. The advertising agencies and World Opportunity Investor note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the company’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for the company’s products and/or services, the company’s ability to fund its capital requirements in the near term and long term, pricing pressures, etc. World Opportunity Investor is the publisher’s trademark. All trademarks used in this advertisement other than World Opportunity Investor are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agencies and World Opportunity Investor are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.